生地黄制剂对前列腺癌晚期患者血清标志物的改善作用与安全性研究  

Effect and safety of Shengdihuang decoction on serum markers of patients with advanced prostate cancer

作　　者：史建华[1] 刘瑞强[1] 尹茂轩[1] 杨帮东[1] 李冠军[2] SHI Jianhua;LIU Ruiqiang;YIN Maoxuan(Department of Urology Surgical,Puyang People Undefineds Hospital(Puyang 457000))

机构地区：[1]河南省濮阳市人民医院泌尿外科,濮阳457000 [2]南阳医学高等专科学校第一附属医院泌尿外科,南阳473000

出　　处：《陕西中医》2019年第8期1073-1076,共4页Shaanxi Journal of Traditional Chinese Medicine

基　　金：河南省医学科技攻关计划项目(201404163)

摘　　要：目的:观察生地黄复方制剂应用于前列腺癌晚期患者治疗中的疗效、安全性及对患者血清标志物的改善作用。方法:选取96例前列腺癌晚期患者作为入选资料,将入选患者均分为对照组与观察组,对照组采取常规治疗,观察组在对照组的基础上应用生地黄复方制剂治疗,两组均以6个月为1个疗程。治疗1个疗程后,评估两组临床疗效,同时观察组治疗前、后两组患者血清标志物表达水平、免疫指标、生活质量、情绪状态及中医证候积分的改善情况,统计两组患者治疗期间不良反应发生情况。结果:观察组整体疗效较对照组理想(P<0.05);治疗后,两组患者PSA、f-PSA、Hb均较前改善(P<0.05),观察组PSA、f-PSA、Hb均优于对照组(P<0.05);治疗后,观察组CD3^+、CD4^+、CD8^+、CD4^+/CD8^+及NK细胞均较治疗前改善(P<0.05),观察组T细胞亚群与NK细胞均优于对照组(P<0.05);治疗后,两组患者生活质量、中医证候与I-PSS均较前改善(P<0.05),观察组各项指标均优于对照组(P<0.05)。对照组不良反应发生率为29.17%,观察组不良反应发生率为10.42%,观察组不良反应发生率低于对照组(P<0.05)。结论:生地黄复方制剂可提高前列腺癌晚期患者临床疗效,降低血清标志物表达水平,改善患者生存质量,并可减少不良反应发生率具有用药安全性高的优势。Objective:To investigate the effect and safety of Shengdihuang decoction on serum markers of patients with advanced prostate cancer. Methods:A total of 96 patients with advanced prostate cancer were admitted. All patients were divided into control group and observation group. The control group was treated with traditional treatment,and the observation group was treated with the compound preparation of rehmannia glutinosa on the basis of the control group. Both groups were treated for 6 months. The expression of serum marker levels,immune index,quality of life,emotional state,and improvement of TCM syndrome scores were compared between 2 groups. The incidence of adverse reactions were recorded during the treatment. Results:The overall efficacy of the observation group was better than that of the control group ( P <0.05). The PSA,f-PSA,Hb were improved after treatment in 2 groups (all P <0.05),and the observation group was superior to the control group ( P <0.05). After treatment,the CD 3 ^+,CD 4 ^+,CD 4 ^+/CD 8 ^+,NK cells of the control group were lower than those before treatment (all P <0.05),and the CD 3 ^+,CD 4 ^+,CD 4 ^+/CD 8 ^+,NK cells of the observation group were higher than those before treatment (all P <0.05). The T-cell subsets and NK cells of the observation group were superior to the control group (all P <0.05). The quality of life,TCM syndrome and I-PSS were improved after treatment in 2 groups (all P <0.05),and the observation group were superior to the control group ( P <0.05). The incidence of adverse reactions was 29.17% in the control group,and was 10.42% in the observation group,respectively ( P <0.05). Conclusion:The efficacy of Shengdihuang compound rehmannia in the treatment of patients with advanced prostate cancer is well,and it can reduce the expression level of serum markers,improve the quality of life,reduce the incidence of adverse reactions,and obtain high safety of medication.

关 键 词：前列腺癌 晚期 生地黄复方制剂 前列腺特异抗原 游离前列腺特异性抗原 生活质量 

分 类 号：R737.25[医药卫生—肿瘤]